Share Price:

APNASPENAspen Pharmacare Hldgs171264 (0.02%)

Investor Relations

Investor Hub

We are a global specialty and branded pharmaceutical company, improving the health of patients across the world through our high quality, affordable medicines. Active at every stage of the value chain, we are uniquely diversified by geography, product and manufacturing capability.

Stephen Saad

Group Chief Executive

Our business strategy is to create value for our stakeholders by promoting access to medicines through building robust product portfolios that achieve organic growth and by leveraging our world-class manufacturing capacities and capabilities. We seek to achieve this by building a differentiated portfolio of relevant IP, creating value through our complex manufacturing capabilities and enabling access through our globally integrated supply chain.

Our market positioning is focused on opportunities presented by emerging markets, balanced with presence in more established, stable developed markets. Through our dynamic portfolio management model, we build, optimise and reshape our basket of products to achieve a global product portfolio of niche, specialty products complemented by leading regional brands, aligned to our manufacturing capability.

We have proven manufacturing capability and capacity, creating access and sustainability collaboration opportunities for multinationals.

Firm Analyst Contact Details

Covering analyst


Raj Sinha

Covering analyst


Letlotlo Lenake

Covering Analyst


Alex Comer

Covering analyst


Luyanda Njilo


Covering Analyst


Roy Campbell

Covering analyst

Standard Bank

Anuja Joshi


Latest Results: H1 2023

Revenue decreased by 1%
(-6% CER) to
R 0 ,2 billion
Dec 2021: R19,4 billion
Normalised EBITDA decreased by 11% (-15% in CER) to
R 0 ,1 billion
Dec 2021: R5,7 billion
Headline earnings per share decreased by 15% (-20% in CER) to
0 cents

Dec 2021: 777.2 cents

Normalised headline earnings per share decreased by 17% (-21% CER) to
0 cents
Dec 2021: 816.4 cents
Dividends per share
10 c

2021: 262c

Shares buyback
R'billion: 0

Share: 10.2 million

4300 %

2021: 7.3%

Leverage ratio
1000 x

2021: 2.1x

Financial Results and Presentations


Interim Results

Annual Results


Interim Results

Annual Results

Interim Results

Additional Presentations and Webcasts

Annual Results

Interim Results

Annual Results

Interim Results

Annual Results

Interim Results

Integrated Reporting

Share Price Information

Financial Calendar

30 August 2023

Annual results:
SENS announcement

31 August 2023

Annual Results Presentation:
In-Person & Webcast

7 December 2023

Annual General Meeting

Closed Period

Aspen is in a closed period from 1 January until the publication of our interim results on the JSE SENS platform scheduled to be released on 1 March 2023.

The live presentation will take place in Cape Town at 08h30 on 2 March 2023.